Clinical Trial Update: A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial comparing IDegLira versus insulin glargine as add-on to SGLT2 inhibitors in type 2 diabetes; completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• IDegLira (insulin degludec/liraglutide)
• Insulin Glargine (insulin glargine)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2018-10-23